Clinical trial
An Open-Label, Dose-Escalation, Phase 1 Study Evaluating the Safety and Tolerability of Weekly Dosing of the Oral Form of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients With Relapsed and Refractory Multiple Myeloma
NCT00963820 is registered in ClinicalTrials.gov with Millennium Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label, Dose-Escalation, Phase 1 Study Evaluating the Safety and Tolerability of Weekly Dosing of the Oral Form of MLN9708, a Second-Generation Proteasome Inhibitor, in Adult Patients With Relapsed and Refractory Multiple Myeloma
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- October 31, 2009
- Completion date
- January 31, 2014
- Enrollment
- 60 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.